Biomarkers of immunosuppressant organ toxicity after transplantation: status, concepts and misconceptions

Bibliography

• Womer KL, Kaplan B. Recent developments in kidney transplantation – a critical assessment. Am J Transplant 2009;9:1265-71
   PubMed Web of Science ®Google Scholar
• Campistol JM, Grinyo JM. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation 2001;71:SS42-51
   PubMed Web of Science ®Google Scholar
• Dunn CJ, Wagstaff AJ, Perry CM, Cyclosporine: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of microemulsion-based formulation (Neoral) in organ transplantation. Drugs 2001;61:1957-2016
   PubMed Web of Science ®Google Scholar
• Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-38
   PubMed Web of Science ®Google Scholar
• Kahan BD. Potential therapeutic interventions to avoid or treat chronic allograft dysfunction. Transplantation 2001;71:SS52-7
   PubMed Web of Science ®Google Scholar
• Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transplant Int 2000;13:313-16
   PubMed Web of Science ®Google Scholar
• Gijtenbeek JM, van den Bent MJ, Vecht CJ. Cyclosporine neurotoxicity: a review. J Neurol 1999;246:339-46
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung CLS, The natural history of chronic allograft rejection. N Engl J Med 2003;349:2326-33
   PubMedGoogle Scholar
• Nankivell BJ, Borrow RJ, Fung CLS, Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557-65
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Chapman JR. Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006;81:643-54
   PubMed Web of Science ®Google Scholar
• Trapp A, Weis M. The impact of immunosuppression on endothelial function. J Cardiovasc Pharmacol 2005;45:81-7
   PubMed Web of Science ®Google Scholar
• Moreno JM, Ruiz MC, Ruiz N, Modulation factors of oxidative status in stable renal transplantation. Transplant Proc 2005;37:1428-30
   PubMed Web of Science ®Google Scholar
• Tepperman E, Ramzy D, Prodger J, Vascular effects of immunosuppression. Can J Surg 2010;53:57-63
   PubMed Web of Science ®Google Scholar
• Lexis LA, Fenning A, Brown L, Antioxidant supplementation enhances erythrocyte antioxidant status and attenuates cyclosporine-induced vascular dysfunction. Am J Transplant 2006;6:41-9
   PubMed Web of Science ®Google Scholar
• Louhelainen M, Merasto S, Finckenberg P, Lipoic acid supplementation prevents cyclosporine-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. J Hypertens 2006;24:947-56
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Ni Z, Zhang YP, Depressed renal and vascular nitric oxide synthase expression in cyclosporine- induced hypertension. Kidney Int 1998;54:482-91
   PubMed Web of Science ®Google Scholar
• Avdonin PV, Cottet-Maire F, Afanasjeva GV, Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int 1999;55:2407-14
   PubMed Web of Science ®Google Scholar
• Josephine A, Amudha G, Veena CK, Oxidative and nitrosative stress mediated renal cellular damage induced by cyclosporine A: role of sulphated polysaccharides. Biol Pharm Bull 2007;30:1254-9
   PubMed Web of Science ®Google Scholar
• Wang C, Salahudeen AK. Lipid peroxidation accompanies cyclosporine nephrotoxicity: effects of vitamin E. Kidney Int 1995;47:927-34
   PubMed Web of Science ®Google Scholar
• Shihab FS, Bennett WM, Yi H, Andoh TF. Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. Transplantation 2005;79:419-26
   PubMed Web of Science ®Google Scholar
• Hauser IA, Schaeffeler E, Gauer S, ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005;16:1501-11
   PubMed Web of Science ®Google Scholar
• Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomize multicenter study. Lancet 2000;356:194-202
   PubMed Web of Science ®Google Scholar
• Kahan BD, Kaplan B, Lorber MI, RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001;71:1400-6
   PubMed Web of Science ®Google Scholar
• Klawitter J, Bendrick-Peart J, Rudolph B, Urine metabolites reflect time-dependent effects of cyclosporine and sirolimus on rat kidney function. Chem Res Toxicol 2009;22:118-28
   PubMed Web of Science ®Google Scholar
• Serkova N, Christians U. Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Invest Drugs 2003;4:1287-96
   PubMedGoogle Scholar
• Christians U, Gottschalk S, Miljus J, Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol 2004;143:388-96
   PubMed Web of Science ®Google Scholar
• Arns W. Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity? Transplant Proc 2007;39:88-93
   PubMed Web of Science ®Google Scholar
• Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 1997;17:75-92
   PubMed Web of Science ®Google Scholar
• DeMattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000;35:333-46
   PubMed Web of Science ®Google Scholar
• Kreis H, Cisterne JM, Land W, Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-60
   PubMed Web of Science ®Google Scholar
• Groth CG, Backman L, Morales JM, Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999;67:1036-42
   PubMed Web of Science ®Google Scholar
• Golshayan D, Pascual M. Minimization of calcineurin inhibitors to improve long-term outcomes in kidney transplantation. Transplant Immunol 2008;20:21-8
   PubMed Web of Science ®Google Scholar
• Pretagostini R, Cinti P, Lai Q, Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Transplant Immunol 2008;20:3-5
   PubMed Web of Science ®Google Scholar
• Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 2004;10:476-82
   PubMedGoogle Scholar
• Opelz G, Dohler B. Discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation 2008;86:371-6
   PubMed Web of Science ®Google Scholar
• Berl T. American Society of Nephrology Renal Research report. J Am Soc Nephrol 2005;16:1886-903
   PubMedGoogle Scholar
• Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006;6:2006-12
   PubMed Web of Science ®Google Scholar
• Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005;16:3015-26
   PubMed Web of Science ®Google Scholar
• Koop R. Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov Today 2005;10:781-8
   PubMed Web of Science ®Google Scholar
• Stojnev S, Pejcic M, Dolicanin Z, Challenges of genomics and proteomics in nephrology. Ren Fail 2009;31:765-72
   PubMed Web of Science ®Google Scholar
• Christians U, Klawitter J, Bendrick-Peart J, Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality and challenges. Ther Drug Monit 2008;30:151-8
   PubMed Web of Science ®Google Scholar
• Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert Opin Med Diagn 2008;2:387-98
   PubMedGoogle Scholar
• Schnackenberg LK. Global metabolic profiling and its role in systems biology to advance personalized medicine in the 21st century. Expert Rev Mol Diagn 2007;7:247-59
   PubMed Web of Science ®Google Scholar
• Anderson NL, Polanski M, Pieper R, The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3:311-26
   PubMed Web of Science ®Google Scholar
• Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83
   PubMed Web of Science ®Google Scholar
• Nobeli I, Thornton JM. A bioinformatician's view of the metabolome. Bioessays 2006;28:534-45
   PubMed Web of Science ®Google Scholar
• Christians U, McCrery S, Klawitter J, Klawitter J. The role of proteomics in the study of kidney diseases and in the development of diagnostic tools. In: Edelstein CL, editor, Biomarkers of kidney disease. Elsevier, San Diego; 2011
   Google Scholar
• Xu EY, Schaefer WH, Xu Q. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. Curr Opin Drug Discov Devel 2009;12:40-52
   PubMed Web of Science ®Google Scholar
• Christians U, Albuisson J, Klawitter J, Klawitter J. The role of metabolomics in the study of kidney diseases and in the development of diagnostic tools. In: Edelstein CL, editor, Biomarkers of kidney disease. Elsevier, San Diego; 2011
   Google Scholar
• Oldiges M, Lutz S, Pflug S, Metabolomics: current state and evolving methodologies and tools. Appl Microbiol Biotechnol 2007;76:495-511
   PubMed Web of Science ®Google Scholar
• Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007;26:51-78
   PubMed Web of Science ®Google Scholar
• Gowda GA, Zhang S, Gu H, Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 2008;8:617-33
   PubMed Web of Science ®Google Scholar
• Want EJ, Nordstrom A, Morita H, From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J Proteome Res 2007;6:459-68
   PubMed Web of Science ®Google Scholar
• Domon B, Aebersold R. Mass spectrometry in protein analysis. Science 2006;312:212-17
   PubMed Web of Science ®Google Scholar
• Aebersol R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422:198-207
   PubMed Web of Science ®Google Scholar
• de Hoog CL, Mann M. Proteomics. Annu Rev Genomics Hum Genet 2004;5:267-93
   PubMed Web of Science ®Google Scholar
• Decramer S, Gonzalez de Peredo A, Breuil B, Urine in clinical proteomics. Mol Cell Proteomics 2008;7:1850-62
   PubMed Web of Science ®Google Scholar
• Muller PY, Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 2009;5:1023-38
   PubMed Web of Science ®Google Scholar
• Lee JW, Figeys D, Vasilescu J. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv Cancer Res 2007;96:269-98
   PubMed Web of Science ®Google Scholar
• Burckart GJ, Amur S, Goodsaid FM, Qualification of biomarkers for drug development in organ transplantation. Am J Transplant 2008;8:267-70
   PubMed Web of Science ®Google Scholar
• Wagner JA, Williams SA, Webster CJ. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007;81:104-7
   PubMed Web of Science ®Google Scholar
• Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001;41:347-66
   PubMed Web of Science ®Google Scholar
• Fawcett T. Introduction to ROC analysis. Pattern Recognit Lett 2006;27:861-74
   Web of Science ®Google Scholar
• Goodsaid FM, Frueh FW, Mattes W. Strategic paths for biomarker qualification. Toxicology 2008;245:219-23
   PubMed Web of Science ®Google Scholar
• Lee JW, Weiner RS, Sailstad JM, Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005;22:499-511
   PubMed Web of Science ®Google Scholar
• Hortin GL. Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin Chem 2005;51:3-5
   PubMed Web of Science ®Google Scholar
• Rodriguez H, Tezak Z, Mesri M, Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem 2010;56:237-43
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine. (2001) Guidance for the Industry. Bioanalytical Method Validation. Version May 2001. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf [Last accessed 29 August 2010]
   Google Scholar
• Clinical and Laboratory Standards Institute. Available from: www.clsi.org [Last accessed 29 August 2010]
   Google Scholar
• European Agency for the Evaluation of Medicinal Products (1995) ICH topic Q2 (R1). Validation of analytical procedures: text and methodology. Note for guidance on analytical procedures: text and methodology. CPMP ICH/381/95. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002662.pdf [Last accessed 29 August 2010)
   Google Scholar
• United States Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for the Industry. Pharmacogenomic data submissions. March 2005. Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126957.pdf [Last accessed 29 August 2010)
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (1998). Guidance for Industry: providing clinical evidence of effectiveness for human drug and biological products. Version May 1998. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf [Last accessed 29 August 2010]
   Google Scholar
• Nickel T, Schlichting L, Weis M. Drugs modulating endothelial function in transplantation. Transplantation 2006;82(1S):S41-6
   PubMedGoogle Scholar
• Rubin C, Nolin TD, Himmelfarb J. Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 2007;16:506-11
   PubMed Web of Science ®Google Scholar
• Conti M, Moutereau S, Esmilaire L, Should kidney tubular markers be adjusted for urine creatinine? The example of urinary cystatin C. Clin Chem Lab Med 2009;47:1553-6
   PubMed Web of Science ®Google Scholar
• Wishart DS. Metabolomics: the principles and potential applications to transplantation. Am J Transplant 2005;5:2814-20
   PubMed Web of Science ®Google Scholar
• Wishart DS. Metabolomics: a complementary tool in renal transplantation. Contrib Nephrol 2008;160:76-87
   PubMed Web of Science ®Google Scholar
• Lenz EM, Bright J, Knight R, Cyclosporin A-induced changes in endogenous metabolites in rat urine: a metabonomic investigation using high field 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. J Pharm Biomed Anal 2004;35:599-608
   PubMed Web of Science ®Google Scholar
• Klawitter J, Haschke M, Kahle C, Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol 2010;70:241-51
   PubMed Web of Science ®Google Scholar
• Schmitz V, Klawitter J, Bendrick-Peart J, Metabolic profiles in urine reflect nephrotoxicity of sirolimus and cyclosporine following rat kidney transplantation. Nephron 2009;111:e80-91
   PubMedGoogle Scholar
• Klawitter J, Klawitter J, Kushner E, Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res 2010;9:865-75
   PubMed Web of Science ®Google Scholar
• Stapenhorst L, Sassen R, Beck B, Hypocitrateuria as a risk factor for nephrocalcinosis after kidney transplantation. Pediatr Nephrol 2005;20:652-6
   PubMed Web of Science ®Google Scholar
• Serkova NJ, Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit 2005;27:733-7
   PubMed Web of Science ®Google Scholar
• Kanaby M, Akcay A, Huddam B, Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc 2005;37:3119-20
   PubMed Web of Science ®Google Scholar
• Perico N, Codreanu I, Caruso M, Hyperuricemia in kidney transplantation. Contrib Nephrol 2005;147:124-31
   PubMed Web of Science ®Google Scholar
• Armstrong KA, Johnson DW, Campbell SB, Does uric acid have a pathogeneric role in graft dysfunction and hypertension in renal transplant patients? Transplantation 2005;80:1565-71
   PubMed Web of Science ®Google Scholar
• Le Moyec L, Pruna A, Eugene M, Proton nuclear magnetic resonance spectroscopy of urine and plasma in renal transplantation follow-up. Nephron 1993;65:433-9
   PubMedGoogle Scholar
• Foxall PJ, Mellotte GJ, Bending MR, NMR spectroscopy as a novel approach to the monitoring of renal transplant function. Kidney Int 1993;43:234-45
   PubMed Web of Science ®Google Scholar
• Knoflach A, Binswanger U. Serum hippuric acid concentration in renal allograft rejection, ureter obstruction, and tubular necrosis. Transpl Int 1994;7:17-21
   PubMed Web of Science ®Google Scholar
• Rush D, Somorjai R, Deslauriers R, Subclinical rejection–a potential surrogate marker for chronic rejection–may be diagnosed by protocol biopsy or urine spectroscopy. Ann Transplant 2000;5:44-9
   PubMedGoogle Scholar
• Wang NJ, Zhou Y, Zhu TY, Prediction of acute cellular renal allograft rejection by urinary metabolomics using MALDI-FTMS. J Proteome Res 2008;7:3597-601
   PubMed Web of Science ®Google Scholar
• Voshol H, Brendlen N, Muller D, Evaluation of biomarker discovery approaches to detect protein biomarkers of acute renal allograft rejection. J Proteome Res 2005;4:1192-9
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, Committee for Medicinal Products for Human Use. Final conclusions on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers. January 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004205.pdf [Last accessed 31 August 2010]
   Google Scholar
• Vaidya VS, Ozer JS, Dieterle F, Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010;28:478-85
   PubMed Web of Science ®Google Scholar
• Dieterle F, Perentes E, Cordier A, Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 2010;28:463-9
   PubMed Web of Science ®Google Scholar
• Bonventre JV, Vaidya VS, Schmouder R, Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010;28:436-40
   PubMed Web of Science ®Google Scholar
• Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr 2008;27:328-39
   PubMed Web of Science ®Google Scholar
• Merrick AB, Bruno ME. Genomic and proteomic profiling for biomarkers and signature profiles of toxicity. Curr Opin Mol Ther 2004;6:600-7
   PubMed Web of Science ®Google Scholar
• Dadhania D, Snopkowski C, Ding R, Validation of noninvasive diagnosis of BK virus nephropathy and identification of prognostic biomarkers. Transplantation 2010;90:189-97
   PubMed Web of Science ®Google Scholar
• Hartono C, Muthukumar T, Suthanthiran M. Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant 2010;15:35-41
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Sharma VK, Ding R, MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci USA 2009;106:5330-5
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008;48:463-8
   PubMed Web of Science ®Google Scholar
• Kellum JA, Levin N, Bouman C, Lameire N. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002;8:509-14
   PubMedGoogle Scholar
• Lee BT, Liew L, Lim J, Candidate List of yoUr Biomarker (CLUB): a web-based platform to aid cancer biomarker research. Biomark Insights 2008;3:65-71
   PubMedGoogle Scholar
• Sistare F, Dieterle F, Troth S, Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol 2010;28:446-54
   PubMed Web of Science ®Google Scholar
• Puntman VO. How-to-guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad Med J 2009;85:538-45
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarker and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95
   PubMed Web of Science ®Google Scholar
• Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-62
   PubMed Web of Science ®Google Scholar
• Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008;134:714-17
   PubMed Web of Science ®Google Scholar
• Nicholson JK. Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2006;2:52
   PubMed Web of Science ®Google Scholar
• Peng J, Gygi SP. Proteomics: the move to mixtures. J Mass Spectrom 2001;36:1083-91
   PubMed Web of Science ®Google Scholar
• Gallego MJ, Zoja C, Morigi M, Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. Am J Kidney Dis 1996;28:23-31
   PubMed Web of Science ®Google Scholar
• Al-Massarani G, Vacher-Coponat H, Paul P, Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation. Am J Transplant 2008;8:2360-7
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Saglam M, Carrero JJ, Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 2009;23:241-8
   PubMed Web of Science ®Google Scholar
• Edwards BS, Hunt SA, Fowler MB, Effect of cyclosporine on plasma endothelin levels in humans after cardiac transplantation. Am J Cardiol 1991;67:782-4
   PubMed Web of Science ®Google Scholar
• Ramzy D, Rao V, Tumiati LC, Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation 2006;114(1 Suppl):I214-19
   PubMedGoogle Scholar
• Muller TF, Vogl M, Neumann MC, Noninvasive monitoring using serum amyloid A and serum neopterin in cardiac transplantation. Clin Chim Acta 1998;276:63-74
   PubMed Web of Science ®Google Scholar
• Maury CP, Teppo AM, Ahonen J. Posttransplantation monitoring of high-density lipoprotein-associated serum amyloid A protein: a new diagnostic aid in the detection of renal allograft rejection. Uremia Invest 1985;9:277-80
   PubMed Web of Science ®Google Scholar
• Aukrust P, Halvorsen B, Yndestad A, Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008;28:1909-19
   PubMed Web of Science ®Google Scholar
• Sahin G, Akay OM, Kus E, Effects of immunosuppressive drugs on platelet aggregation and soluble P-selectin levels in renal transplant patients. Ren Fail 2009;31:111-17
   PubMed Web of Science ®Google Scholar
• Aharinejad S, Krenn K, Zuckermann A, Matrix metalloproteases and their tissue inhibitor in cardiac transplantation. Eur J Cardiothorac Surg 2007;32:48-51
   PubMed Web of Science ®Google Scholar
• Caglar K, Yilmaz MI, Saglam M, Endothelial dysfunction and fetuin A levels before and after kidney transplantation. Transplantation 2007;83:392-7
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Saglam M, Caglar K, Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005;80:1660-6
   PubMed Web of Science ®Google Scholar
• Nouri-Majalan N, Masoumi R, Nafisi R, Relationship between serum homocysteine and other parameters in renal transplant patients. Transplant Proc 2009;41:2826-8
   PubMed Web of Science ®Google Scholar
• Lexis LA, Fenning A, Brown L, Antioxidant supplementation enhances erythrocyte antioxidant status and attenuates cyclosporine-induced vascular dysfunction. Am J Transplant 2006;6:41-9
   PubMed Web of Science ®Google Scholar
• Vural A, Yilmaz MI, Caglar K, Assessment of oxidative stress in the early posttransplant period: comparison of cyclosporine A and tacrolimus-based regimens. Am J Nephrol 2005;25:250-5
   PubMed Web of Science ®Google Scholar
• Betton GR, Kenne K, Somers R, Marr A. Protein biomarkers of nephrotoxicity; a review and findings with cyclosporin A, a signal transduction kinase inhibitor and N-phenylanthranilic acid. Cancer Biomark 2005;1:59-67
   PubMedGoogle Scholar
• Aicher L, Wahl D, Arce A, New insights into cyclosporine A nephrotoxicity by proteome analysis. Electrophoresis 1998;19:1998-2003
   PubMed Web of Science ®Google Scholar
• Aicher L, Meier G, Norcross AJ, Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization. Biochem Pharmacol 1997;53:723-31
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Sarnak MJ, Katz R, Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-60
   PubMed Web of Science ®Google Scholar
• Conti M, Moutereau S, Zater M, Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med 2006;44:288-91
   PubMed Web of Science ®Google Scholar
• Le Bricon T, Thervet E, Benlakehal M, Changes in plasma cystatin C after renal transplantation and acute rejection in adults. Clin Chem 1999;45:2243-9
   PubMed Web of Science ®Google Scholar
• Yang GP, Lau LF. Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ 1991;2:351-7
   PubMedGoogle Scholar
• Muramatsu Y, Tsujie M, Kohda Y, Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int 2002;62:1601-10
   PubMed Web of Science ®Google Scholar
• Sundberg AG, Nilsson R, Appelkvist EL, Dallner G. Immuno-histochemical localization of alpha and pi class glutathione transferases in normal human tissues. Pharmacol Toxicol 1993;72:321-31
   PubMedGoogle Scholar
• Sundberg AG, Appelkvist EL, Backman L, Dallner G. Urinary pi-class glutathione transferase as an indicator of tubular damage in the human kidney. Nephron 1994;67:308-16
   PubMedGoogle Scholar
• Backman L, Appelkvist EL, Ringden O, Dallner G. Glutathione transferase in the urine: a marker for post-transplant tubular lesions. Kidney Int 1988;33:571-7
   PubMed Web of Science ®Google Scholar
• Harrison DJ, Kharbanda R, Cunningham DS, Distribution of glutathione S-transferase isoenzymes in human kidney: basis for possible markers of renal injury. J Clin Pathol 1989;42:624-8
   PubMed Web of Science ®Google Scholar
• Eijkenboom JJ, van Eijk LT, Pickkers P, Small increases in the urinary excretion of glutathione S-transferase A1 and P1 after cardiac surgery are not associated with clinically relevant renal injury. Intensive Care Med 2005;31:664-7
   PubMed Web of Science ®Google Scholar
• Pelsers MM. Fatty acid-binding protein as marker for renal injury. Scand J Clin Lab Invest 2008;241(Suppl):73-7
   Google Scholar
• Sanchez-Pozos K, Lee-Montiel F, Perez-Villalva R, Polymerized type I collagen reduces chronic cyclosporine nephrotoxicity. Nephrol Dial Transplant 2010;25:2150-8
   PubMed Web of Science ®Google Scholar
• Fernandes I, Zhang Y, Qi Y, Impact of reduced nephron mass on cyclosporine- and/or sirolimus-induced nephrotoxicity. Transplantation 2009;88:1323-31
   PubMed Web of Science ®Google Scholar
• Perez-Rojas J, Blanco JA, Cruz C, Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007;292:F131-9
   PubMed Web of Science ®Google Scholar
• Ichimura T, Asseldonk EJ, Humphreys BD, Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 2008;118:1657-68
   PubMed Web of Science ®Google Scholar
• Vaidya VS, Ramirez V, Ichimura T, Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006;290:F517-29
   PubMed Web of Science ®Google Scholar
• Han WK, Bailly V, Abichandani R, Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62:237-44
   PubMed Web of Science ®Google Scholar
• Hong ME, Hong JC, Stepkowski S, Kahan BD. Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene. Transplant Proc 2005;37:4254-8
   PubMed Web of Science ®Google Scholar
• Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver- and the heart-type fatty acid-binding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 1992;288:285-90
   PubMed Web of Science ®Google Scholar
• Kamijo A, Sugaya T, Hikawa A, Clinical evaluation of urinary excretion of liver-type fatty acid binding protein as a marker for monitoring chronic kidney disease: a multi-center trial. J Lab Clin Med 2005;145:125-33
   PubMed Web of Science ®Google Scholar
• Duraj FF, Backman L, Dati F, Ringden O. Serum levels of alpha-1 microglobulin and beta-2 microglobulin in bone marrow transplant recipients treated with cyclosporin A. Transpl Int 1991;4:146-50
   PubMed Web of Science ®Google Scholar
• Backman L, Ringden O, Bjorkhem I, Lindback B. Increased serum beta 2 microglobulin during rejection, cyclosporine-induced nephrotoxicity, and cytomegalovirus infection in renal transplant recipients. Transplantation 1986;42:368-71
   PubMed Web of Science ®Google Scholar
• Davey PG, Cowley DM, Geddes AM, Terry J. Clinical evaluation of beta 2-microglobulin, muramidase, and alanine aminopeptidase as markers of gentamicin nephrotoxicity. Contrib Nephrol 1984;42:100-6
   PubMedGoogle Scholar
• Tolkoff-Rubin NE, Rubin RH, Bonventre JV. Non-invasive renal diagnostic studies. Clin Lab Med 1988;8:507-26
   PubMed Web of Science ®Google Scholar
• Miyata T, Jadoul M, Kurokawa K, Van Ypersele de Strihou C. Beta-2 microglobulin in renal disease. J Am Soc Nephrol 1998;9:1723-35
   PubMed Web of Science ®Google Scholar
• Palmieri L, Ronca G, Cioni L, Puccini R. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase, alanine aminopeptidase and lysozyme in patients with renal disease. Contrib Nephrol 1984;42:123-9
   PubMedGoogle Scholar
• Diener U, Knoll E, Ratge D, Urinary excretion of alanine-aminopeptidase and N-acetyl-beta-D-glucosaminidase during sequential combination chemotherapy. J Clin Chem Clin Biochem 1982;20:615-19
   PubMedGoogle Scholar
• Liangos O, Perianayagam MC, Vaidya VS, Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 2007;18:904-12
   PubMed Web of Science ®Google Scholar
• Gruber SA, Gallichio M, Rosano TG, Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipients. J Clin Pharmacol 1997;37:575-86
   PubMed Web of Science ®Google Scholar
• Marchewka Z, Kuzniar J, Dlugosz A. Enzymatic markers of cyclosporine nephrotoxicity in patients after renal transplantation. Int Urol Nephrol 1999;31:727-34
   PubMedGoogle Scholar
• Bornstein B, Arenas J, Morales JM, Cyclosporine nephrotoxicity and rejection crisis: diagnosis by urinary enzyme excretion. Nephron 1996;72:402-6
   PubMedGoogle Scholar
• Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, Michaluk-Skutnik J. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol 2010;25:889-97
   PubMed Web of Science ®Google Scholar
• Haase M, Bellomo R, Devarajan P, NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:1012-24
   PubMed Web of Science ®Google Scholar
• Mishra J, Dent C, Tarabishi R, Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365(9466):1231-8
   PubMed Web of Science ®Google Scholar
• Mishra J, Ma Q, Prada A, Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534-43
   PubMed Web of Science ®Google Scholar
• Camara NO, Matos AC, Rodrigues DA, Early detection of heart transplant patients with increased risk of ciclosporin nephrotoxicity. Lancet 2001;357:856-7
   PubMed Web of Science ®Google Scholar
• Bernard AM, Vyskocil AA, Mahieu P, Lauwerys RR. Assessment of urinary retinol-binding protein as an index of proximal tubular injury. Clin Chem 1987;33:775-9
   PubMed Web of Science ®Google Scholar
• Camara NO, Matos AC, Rodrigues DA, Urinary retinol binding protein is a good marker of progressive cyclosporine nephrotoxicity after heart transplant. Transplant Proc 2001;33:2129-31
   PubMed Web of Science ®Google Scholar
• McDonough AA, Biemesderfer D. Does membrane trafficking play a role in regulating the sodium/hydrogen exchanger isoform 3 in the proximal tubule? Curr Opin Nephrol Hypertens 2003;12:533-41
   PubMed Web of Science ®Google Scholar
• Ruiz P, Tryphonopoulos P, Island E, Citrulline evaluation in bowel transplantation. Transplant Proc 2010;42:54-6
   PubMed Web of Science ®Google Scholar
• David AI, Selvaggi G, Ruiz P, Blood citrulline level is an exclusionary marker for significant acute rejection after intestinal transplantation. Transplantation 2007;84:1077-81
   PubMed Web of Science ®Google Scholar
• Gondolesi G, Ghirardo S, Raymond K, The value of plasma citrulline to predict mucosal injury in intestinal allografts. Am J Transplant 2006;6:2786-90
   PubMed Web of Science ®Google Scholar
• David AI, Gaynor JJ, Zis PP, An association of lower serum citrulline levels within 30 days of acute rejection in patients following small intestine transplantation. Transplant Proc 2006;38:1731-2
   PubMed Web of Science ®Google Scholar
• Pappas PA, Tzakis AG, Gaynor JJ, An analysis of the association between serum citrulline and acute rejection among 26 recipients of intestinal transplant. Am J Transplant 2004;4:1124-32
   PubMed Web of Science ®Google Scholar
• Cagnola H, Scaravonati R, Cabanne A, Evaluation of calprotectin level in intestinal content as an early marker for graft rejection. Transplant Proc 2010;42:57-61
   PubMed Web of Science ®Google Scholar
• Sindhi R, AshokKumar C, Mazariegos G, Immune monitoring in small bowel transplantation. Curr Opin Organ Transplant 2010;15:349-56
   PubMed Web of Science ®Google Scholar
• Akpinar E, Vargas J, Kato T, Fecal calprotectin level measurements in small bowel allograft monitoring: a pilot study. Transplantation 2008;85:1281-6
   PubMed Web of Science ®Google Scholar
• Sudan D, Vargas L, Sun Y, Calprotectin: a novel noninvasive marker for intestinal allograft monitoring. Ann Surg 2007;246:311-15
   PubMed Web of Science ®Google Scholar
• Pakarinen MP, Kuusanmaki P, Lauronen J, Effects of ileum transplantation and chronic rejection on absorption and synthesis of cholesterol in pigs. Pediatr Surg Int 2003;19:656-61
   PubMed Web of Science ®Google Scholar
• Nikkila K, Miettinen TA, Hockerstedt KV, Isoniemi H. Sterol parameters as markers of liver function in primary biliary cirrhosis before and after liver transplantation. Transpl Int 2005;18:221-5
   PubMed Web of Science ®Google Scholar
• Ritchie BK, Brewster DR, Davidson GP, 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health. Pediatrics 2009;124:620-6
   PubMed Web of Science ®Google Scholar
• Johansson JE, Ekman T. Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study. Bone Marrow Transplant 1999;24:35-9
   PubMed Web of Science ®Google Scholar
• Musso CG, Michelangelo H, Vilas M, Creatinine reabsorption by the aged kidney. Int Urol Nephrol 2009;41:727-31
   PubMed Web of Science ®Google Scholar